RUA Life Sciences (GB:RUA) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
RUA Life Sciences reports a robust first-half revenue growth, doubling from last year, driven by increased biomaterials royalties and contract manufacturing revenues. The group’s strategic acquisition of Abiss Group has bolstered its financial standing, with a pre-tax profit of £0.4 million, a significant recovery from a loss last year. The company is also adjusting its accounting year to align better with business planning.
For further insights into GB:RUA stock, check out TipRanks’ Stock Analysis page.
